Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 15284112

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2004 Nov 15
First author
Forstpointner R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Forstpointner R
      type
      Author
    2. name
      Dreyling M
      type
      Author
    3. name
      Repp R
      type
      Author
    4. name
      Hermann S
      type
      Author
    5. name
      Hänel A
      type
      Author
    6. name
      Metzner B
      type
      Author
    7. name
      Pott C
      type
      Author
    8. name
      Hartmann F
      type
      Author
    9. name
      Rothmann F
      type
      Author
    10. name
      Rohrberg R
      type
      Author
    11. name
      Böck HP
      type
      Author
    12. name
      Wandt H
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Forstpointner R
      type
      Author
    2. name
      Dreyling M
      type
      Author
    3. name
      Repp R
      type
      Author
    4. name
      Hermann S
      type
      Author
    5. name
      Hänel A
      type
      Author
    6. name
      Metzner B
      type
      Author
    7. name
      Pott C
      type
      Author
    8. name
      Hartmann F
      type
      Author
    9. name
      Rothmann F
      type
      Author
    10. name
      Rohrberg R
      type
      Author
    11. name
      Böck HP
      type
      Author
    12. name
      Wandt H
      type
      Author
    bibliography ids
    1. nci-bib-925484dd67728a6551fc7280
    book metadata
    content sha256
    3151d1fcf23ac02fb215ef03059d8e97e854822390519e914e2c7ce7531223a1
    document type
    citation
    dois
    1. 10.1182/blood-2004-04-1323
    electronic publication date
    display
    2004 Jul 29
    precision
    day
    year
    2004
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:15284112
    immutable id
    pubmed:15284112@3151d1fcf23ac02fb215ef03059d8e97e854822390519e914e2c7ce7531223a1
    journal
    abbreviation
    Blood
    issn electronic
    Source null
    issn print
    0006-4971
    issue
    10
    name
    Blood
    nlm unique id
    7603509
    pages
    3064-71
    volume
    104
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      15284112
      provenance
      batch id
      748437a772c9631ad901
      provider
      NCBI PubMed ESummary
      record sha256
      a5b4255c3776a301d56203274de85e4dd2288ab86e73eae11949d5f569a17045
      response sha256
      1535c16de1ca2ef53b01ccf9e7709049035aa1b159955f06fbec3d1a0daddc80
      retrieved at
      2026-09-09T23:45:55.399079+00:00
      publication date
      display
      2004 Nov 15
      precision
      day
      year
      2004
      publication types
      1. Clinical Trial
      2. Clinical Trial, Phase III
      3. Journal Article
      4. Multicenter Study
      5. Randomized Controlled Trial
      6. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/15284112/
      title
      The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

      Preserved source evidence · Independent clinical review pending · Not medical advice